Since the early 2000's, chikungunya has been considered to be a rapidly expanding, re-emerging, tropical disease. This led the National Institute of Allergy and Infectious Diseases (NIAID) together with the World Health Organization (WHO) to organize an expert consultation in June 2015. At the meeting, the major socioeconomic impact and the large public health burden, due to a high rate of debilitating, chronic arthritis and other co-morbidities, were highlighted. Some evidencewas also found that chikungunya is likely to remain a difficult infection to prevent or control, even when vaccines and effective treatments become available [1]. Thus, regarding the low fatality rate, one major challenge of chikungunya epidemics in coming years will be the management of the chronic stage.